Gemigliptin added to ongoing metformin therapy provides sustained glycaemic control over 52 weeks and was well tolerated in patients with type 2 diabetes

被引：0
|
作者：
Rhee, E. J. [1 ]
Min, K. W. [2 ]
Jang, H. C. [3 ]
Chung, C. H. [4 ]
Nam-Goong, I. S. [5 ]
Bae, H. Y. [6 ]
Baik, S. H. [7 ]
Shivane, V. K. [8 ]
Sosale, A. R. [9 ]
Dharmalingam, M. [10 ]
Gandhi, P. [11 ]
Gupta, S. K. [12 ]
Ahn, J. Y. [13 ]
Bang, K. S. [13 ]
Lee, M. K. [14 ]
机构：
[1] Kangbuk Samsung Med Ctr, Seoul, South Korea
[2] Eulji Univ, Sch Med, Seoul, South Korea
[3] Seoul Natl Univ, Bundang Hosp, Songnam, South Korea
[4] Wonju Christian Hosp, Wonju, South Korea
[5] Ulsan Univ Hosp, Ulsan, South Korea
[6] Chosun Univ Hosp, Kwangju, South Korea
[7] Korea Univ, Guro Hosp, Seoul, South Korea
[8] Shivane, Mumbai, Maharashtra, India
[9] Diacon Hosp, Diabet Care & Res Ctr, Bangalore, Karnataka, India
[10] Bangalore Endocrinol & Diabet Res Ctr, Bangalore, Karnataka, India
[11] Gandhi Res Inst, Nagpur, Maharashtra, India
[12] MV Hosp & Res Ctr, Lucknow, Uttar Pradesh, India
[13] LG Life Sci, Seoul, South Korea
[14] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
来源：
DIABETOLOGIA | 2013年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
111
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [1] Once-daily saxagliptin added to metformin is well tolerated and provides sustained glycaemic control over 102 weeks in patients with type 2 diabetes
    Ravichandran, S.
    DeFronzo, R.
    Garber, A. J.
    Gross, J. L.
    Hissa, M. N.
    Duan, R. Y.
    Chen, R.
    DIABETOLOGIA, 2009, 52 : S60 - S60
  • [2] Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks
    Pfuetzner, A.
    Paz-Pacheco, E.
    Allen, E.
    Frederich, R.
    Chen, R.
    DIABETES OBESITY & METABOLISM, 2011, 13 (06): : 567 - 576
  • [3] Once-Daily Saxagliptin Added to Metformin Provides Sustained Glycemic Control and Is Well Tolerated over 102 Weeks in Patients with T2D
    Defronzo, Ralph A.
    Hissa, Miguel N.
    Garber, Alan J.
    Gross, Jorge Luiz
    Duan, Raina Yuyan
    Ravichandran, Shoba
    Chen, Roland
    DIABETES, 2009, 58 : A147 - A147
  • [4] Efficacy and safety of gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
    Rhee, E. J.
    Min, K. W.
    Jang, H. C.
    Chung, C. H.
    Nam-Goong, I. S.
    Bae, H. Y.
    Lee, M. K.
    Baik, S. H.
    Shivane, V. K.
    Sosale, A. R.
    Dharmalingam, M.
    Gandhi, P.
    Gupta, S. K.
    Kim, J. A.
    Kim, S. W.
    DIABETOLOGIA, 2012, 55 : S352 - S352
  • [5] Efficacy and Safety of Gemigliptin Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone
    Rhee, Eun Jung
    Min, Kyung Wan
    Jang, Hak Chul
    Nam-Goong, Il Seong
    Chung, Choon Hee
    Park, Joong Yeol
    Bae, Hak Yeon
    Kim, Doo-Man
    Baik, Sei Hyun
    Lee, Moon-Kyu
    Kim, Byung-Joon
    Chang, Sang Ah
    Ahn, Chul Woo
    Kim, Yong Seong
    Yoon, Kun Ho
    Park, Kyong Soo
    Kim, Hae Jin
    Shivane, Vyankatesh K.
    Sosale, Aravind R.
    Dharmalingam, Mala
    Gandhi, Pramod
    Gupta, Sandeep Kumar
    Pitale, Shailesh
    Agarwal, Pankaj Kumar
    Rais, Nadeem
    Mohan, V.
    Mahesh, Uma
    Kim, Jeong Ae
    Kim, Pan Kyung
    Kim, Sun Woo
    DIABETES, 2012, 61 : A291 - A291
  • [6] Sitagliptin added to ongoing metformin therapy provides sustained glycemic control over 54 weeks, with a low incidence of hypoglycemia and with weight loss
    Karasik, Avraham
    Wu, Mei
    Williams-Herman, Debora
    Meininger, Gary
    DIABETES, 2007, 56 : A139 - A139
  • [7] Sitagliptin added to ongoing treatment with metformin improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes (T2DM)
    Kadowaki, Takashi
    Tajima, Naoko
    Odawara, Masato
    Nishii, Mikio
    Nonaka, Kenji
    Stein, Peter P.
    DIABETES, 2008, 57 : A589 - A590
  • [8] Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52weeks
    Kadowaki, Takashi
    Tajima, Naoko
    Odawara, Masato
    Nishii, Mikio
    Taniguchi, Tadaaki
    Ferreira, Juan Camilo Arjona
    JOURNAL OF DIABETES INVESTIGATION, 2013, 4 (02) : 174 - 181
  • [9] Saxagliptin Initial Combination with Metformin Provides Sustained Glycemic Control and Is Well Tolerated in Patients with Type 2 Diabetes: 76-Week Results
    Pfuetzner, Andreas
    Paz-Pacheco, Elizabeth
    Berglind, Niklas
    Allen, Elsie
    Frederich, Bob
    Chen, Roland
    DIABETES, 2010, 59 : A17 - A18
  • [10] Once-daily sitagliptin monotherapy provides effective glycemic control over 54 weeks and is well tolerated in patients with type 2 diabetes
    Aschner, Pablo
    Lunceford, Jared
    Williams-Herman, Debora
    DIABETES, 2007, 56 : A553 - A553
12345